Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic‐ischaemic encephalopathy

Tejasvi Chaudhari; William McGuire

doi:10.1002/14651858.CD006817.pub3

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Respuestas clínicas Cochrane
Guías
Temas

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Figure 1

Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.1 Death during the neonatal period and infancy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 2

Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.2 Death or severe neurodevelopmental disability.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 3

Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.3 Severe quadriplegia in surviving infants.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 4

Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.4 Seizures during the neonatal period.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 5

Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.5 Abnormalities on brain imaging.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 6

'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 Allopurinol versus control (placebo or no drug), Outcome 1 Death during the neonatal period and infancy.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Allopurinol versus control (placebo or no drug), Outcome 2 Death or severe neurodevelopmental disability.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Allopurinol versus control (placebo or no drug), Outcome 3 Severe quadriplegia in surviving infants.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 Allopurinol versus control (placebo or no drug), Outcome 4 Seizures during the neonatal period.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 Allopurinol versus control (placebo or no drug), Outcome 5 Abnormalities on brain imaging.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. Allopurinol versus control (placebo or no drug)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death during the neonatal period and infancy Show forest plot	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

1.1 All infants	3	114	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.56, 1.38]
1.2 Infants with severe encephalopathy	2	41	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.62, 1.51]
2 Death or severe neurodevelopmental disability Show forest plot	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

2.1 All infants	3	110	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.56, 1.08]
2.2 Infants with severe encephalopathy	2	41	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.66, 1.30]
3 Severe quadriplegia in surviving infants Show forest plot	3	73	Risk Ratio (M‐H, Fixed, 95% CI)	0.59 [0.28, 1.27]

4 Seizures during the neonatal period Show forest plot	3	114	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.75, 1.16]

5 Abnormalities on brain imaging Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only

5.1 Cranial ultrasound	1	31	Risk Ratio (M‐H, Fixed, 95% CI)	1.12 [0.81, 1.55]
5.2 Magnetic resonance imaging (surviving infants)	1	9	Risk Ratio (M‐H, Fixed, 95% CI)	1.88 [0.56, 6.31]

Comparison 1. Allopurinol versus control (placebo or no drug)

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet